Non-microcytic lung cancer (CPNM) in stage III consists of a heterogeneous population with two subsets: stage IIIA and IIIB. Most patients with stage IIIA / B have an inoperable (non-resectable) disease. Only a third of patients with stage IIIA disease are considered operable. Approximately 20-30% of patients with CPNM are diagnosed in stage III non-candidates for surgical treatment, but may be likely to receive chemoradiation treatment with curative intent. The prognosis of inoperable stage III CPNM remains poor and long-term survival rates are low.
Durvalumab; Lung cancer; Neoplasia; Immunotherapy
Programa d'Harmonització Farmacoterapèutica. Durvalumab per al tractament del càncer de pulmó no microcític estadi III irresecable. Barcelona: Servei Català de la Salut; 2020.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/5392
This item appears in following collections
The following license files are associated with this item: